Item 5. Other Information

3K characters. Original on sec.gov · Markdown

Item 5. Other Information

Rule 10b5-1 Trading Plans

Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The following table describes the written plans for the sale of our securities adopted by our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) during the third quarter of 2025, and one from the second quarter of 2025 that was previously not disclosed, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).


Name and Title	Date of Adoption of Trading Plan	Scheduled Expiration Date of Trading Plan (1)	Maximum Shares Subject to Trading Plan
Carmen Bozic EVP, Global Medicines Development and Medical Affairs, Chief Medical Officer	5/30/2025	11/21/2025		19,404
Kristen Ambrose SVP, Chief Accounting Officer	8/08/2025	8/03/2026		7,539(2)
Jeffrey Leiden Executive Chairman	8/06/2025	1/21/2026		144,644
E. Morrow "Morrey" Atkinson, III EVP, Chief Technical Operations Officer, Head of Biopharmaceuitcal Sciences and Manufacturing Operations	8/11/2025	4/30/2026		12,709(2)
Ourania "Nia" Tatsis EVP, Chief Regulatory and Quality Officer	8/21/2025	7/31/2026		24,301(2)


(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.

Previous: Item 1A. Risk Factors · Next: Item 6. Exhibits